News
Press Releases
-
Recor Medical Names Dr. Helen Reeve-Stoffer Chief Executive Officer
Palo Alto, CA, USA – May 15, 2026 – In recognition of World Hypertension Day 2026, taking place on Sunday, May 17, Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., joins the global community in raising awareness of high blood pressure and celebrating the progress being made in its…
-
Recor Medical Highlights Innovation and Global Action on World Hypertension Day 2026
Palo Alto, CA, USA – May 15, 2026 – In recognition of World Hypertension Day 2026, taking place on Sunday, May 17, Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., joins the global community in raising awareness of high blood pressure and celebrating the progress being made in its…
-
Recor Medical’s Paradise Ultrasound Renal Denervation System Honored with TAG Award for Cardiovascular Therapeutic Innovation
Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced that the Paradise™ Ultrasound Renal Denervation (uRDN) system has been recognized with a TAG award in the Medical Devices: Cardiovascular Therapeutic Innovation category.
-
Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension, Now Covered by Insurance and Commercially Available in Japan
Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective March 1. Following the inception of insurance coverage, Otsuka Medical Devices has commenced sales of the system on March 2 and…
-
Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 Months with Recor Medical’s Paradise Ultrasound Renal Denervation System
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced results from two clinical studies presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference this week: data from the Global Paradise System (GPS) Registry demonstrated a 19.6 mmHg reduction in office systolic blood pressure at six months with…
-
CMS Issues National Coverage Determination for Recor Medical’s Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced that the Centers for Medicare and Medicaid Services (CMS) has issued its National Coverage Determination (NCD) for Renal Denervation (RDN), including Recor’s Paradise® Ultrasound Renal Denervation (uRDN) system, a device-based therapy for patients with uncontrolled hypertension whose blood…
-
Recor Medical Announces Paradise Ultrasound Renal Denervation System Receives Manufacturing and Marketing Approval in Japan for the Treatment of Resistant Hypertension
Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the Paradise™ Ultrasound Renal Denervation (uRDN) system has received approval for manufacturing and marketing in Japan for the treatment of resistant hypertension. This marks the first approval in the country for a medical device indicated for the disease.
-
Recor Medical Responds to the American Heart Association (AHA) and American College of Cardiology’s (ACC) Updated Guidelines on Renal Denervation for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), appreciate the American Heart Association (AHA) and American College of Cardiology (ACC) for highlighting renal denervation (RDN) as a therapeutic option for resistant or uncontrolled hypertension in the joint 2025 Guidelines. The AHA/ACC Guidelines integrate the latest scientific data,…
-
Recor Medical Supports Proposed CMS National Coverage Determination of Renal Denervation for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced their support for the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) for Renal Denervation (RDN), a device-based therapy for patients with uncontrolled hypertension—individuals whose blood pressure cannot be properly managed with lifestyle…
-
Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
May 17, 2025, is World Hypertension Day, a day dedicated to raising awareness about high blood pressure, also known as the “silent killer” because many people do not know they have it and, over time, it can lead to serious health issues. The theme of World Hypertension Day, “Measure Your Blood Pressure Accurately, Control It,…
-
Recor Medical Statement on CMS National Coverage Analysis of Renal Denervation for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that the Centers for Medicare and Medicaid Services (CMS) have begun a National Coverage Analysis (NCA) of Renal Denervation (RDN), a medical device-based treatment for hypertension.
-
Recor Medical Announces CMS Grant of Transitional Pass-Through (TPT) Payment for Recor’s Paradise Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced U.S. Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise® Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal…
-
Recor Medical Endorses European Society of Cardiology’s New Guidelines for Management of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) have endorsed the updated recommendations for the management of hypertension by the European Society of Cardiology (ESC), which were presented at the ESC Congress on Friday, August 30, 2024. The new guidelines, “2024 ESC Guidelines for the management of elevated…
-
Recor Medical Responds to the American Heart Association’s (AHA) Scientific Statement on Renal Denervation for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) greatly appreciate the American Heart Association (AHA) for providing a well-considered statement on the application of renal denervation (RDN) as a therapy option to treat high blood pressure. The AHA scientific statement was based on a balanced literature review…
-
CMS Approves Additional Payment for Recor Medical’s Paradise Ultrasound Renal Denervation System in Hospital Inpatient Cases
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announced today that the Centers for Medicare and Medicaid Services (CMS) published the Final Rule for Fiscal Year 2025 Hospital Inpatient Prospective Payment Systems (IPPS), approving a New Technology Add-On Payment (NTAP) for the Paradise™ Ultrasound Renal Denervation (uRDN)…
-
First Patients Treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS) for the Treatment of Uncontrolled Hypertension with Ultrasound Renal Denervation
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the first patients in the US have been treated in Recor Medical’s Global Paradise® System US Post Approval Study (US GPS), a real-world study gathering data on the long-term safety and effectiveness of ultrasound renal denervation (uRDN). Dr. Antonio…
-
Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
Hypertension, or high blood pressure, affects nearly half of all Americans and more than one billion people worldwide. Hypertension is known as the “silent killer” because many people do not know they have it and, over time, it can lead to serious health issues. Hypertension is the number one contributor to the burden of human…
-
Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), announce the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension in the United Arab Emirates (UAE). Three cases were performed at Al Qassimi Hospital in Sharjah by Dr. Arif Al Nooryani and…
-
Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States. The first commercial procedures took place at NewYork-Presbyterian/Columbia University Irving…
-
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
-
Recor Medical Announces Positive Results from Six-Month Pooled Analysis of Data from the RADIANCE Global Clinical Trial Program at TCT 2023
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced positive results from a combined analysis of six-month follow-up data from the three RADIANCE global clinical studies evaluating the Paradise™ Ultrasound Renal Denervation (uRDN) system as a treatment for hypertension. Analysis demonstrated maintained blood pressure (BP) reduction…
-
Recor Medical to Present Latest Clinical Data on Paradise® Ultrasound Renal Denervation at TCT Annual Meeting
Recor Medical, Inc. (“Recor”), a subsidiary of Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), will present data from several clinical studies of the Paradise® Ultrasound Renal Denervation (uRDN) system in the treatment of hypertension at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco.
-
ReCor Responds to European Society of Hypertension’s (ESH) Updated Guidelines for Management of Arterial Hypertension
ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection. The new guidelines are designed to serve…
-
ReCor Medical Announces Two Concurrent JAMA Network Publications of Study Results on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that primary endpoint results from the RADIANCE II pivotal trial were published in the Journal of the American Medical Association (JAMA). Study results showed that the Paradise Ultrasound Renal Denervation (uRDN) System successfully reduced blood pressure compared to…
-
ReCor Medical Names Lara Barghout President and Chief Executive Officer
ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the appointment of Lara Barghout as President and Chief Executive Officer of ReCor. Ms. Barghout will lead the ReCor business strategy and organization in an exciting new direction: the global commercialization of ReCor’s Paradise™ Ultrasound Renal Denervation…
-
ReCor Medical and Otsuka Medical Devices Announce Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration
ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the filing of the pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Paradise™ uRDN System in the treatment of uncontrolled hypertension.
-
ReCor Medical Announces Consistent Reduction of Blood Pressure in Pooled Analysis of Three Clinical Trials at AHA 2022
ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. today announced consistent and significant blood pressure (“BP”) lowering results across a range of patients with uncontrolled hypertension, including across differences in age, sex, baseline blood pressure, medication level and ethnicity. The results come from analysis of the pooled data from ReCor’s RADIANCE…